News Releases

18 Jan '22
Reykjavik  (January 18, 2022) — Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (“Oaktree II”) (NYSE: OACB), a publicly traded special
16 Dec '21
Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the European Union (EU) follows the recommendation of the Committee for Medicinal Products
08 Oct '21
U.S. Federal Judge Grants Alvotech’s Motion to Dismiss AbbVie’s lawsuit alleging misappropriation of trade secrets. A U.S. federal judge has dismissed a lawsuit brought by AbbVie against Alvotech Hf alleging theft of trade secrets. Alvotech, is seeking to bring an affordable high-concentration
Displaying 11 - 20 of 55